Ligand Pharmaceuticals (LGND) Net Margin (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Net Margin of 25.8% for Q1 2026, down 134.38% sequentially from 75.06% in Q4 2025, and up 6784.0% YoY from 0.37% in Q1 2025.
Ligand Pharmaceuticals (LGND) Net Margin (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Net Margin for 15 years, with the latest figure at 25.8% in Q1 2026.
- Quarterly Net Margin rose 6784.0% year-over-year to 25.8% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 55.95% (up 9647.0% YoY) and the FY2025 annual result came in at 46.42%, up 4884.0% from the prior year.
- Net Margin declined to 25.8% in Q1 2026 per LGND's latest filing, from 75.06% in the prior quarter.
- Over five years, Net Margin peaked at 101.57% in Q3 2025 and troughed at 93.64% in Q1 2025.
- A 5-year average of 5.83% and a median of 6.73% in 2022 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2025: Net Margin tumbled 1967 bps in 2022, then surged 14767 bps in 2025.
- Over 5 years, Net Margin stood at 5.86% in 2022, then soared by 35 bps to 3.79% in 2023, then tumbled by 1818 bps to 72.62% in 2024, then soared by 203 bps to 75.06% in 2025, then sank by 134 bps to 25.8% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 25.8%, 75.06%, and 101.57% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 76.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 76.16% |
| Mar 31, 2026 | -25.80% |
| Dec 31, 2025 | 75.06% |
| Sep 30, 2025 | 101.57% |
| Jun 30, 2025 | 10.18% |
| Mar 31, 2025 | -93.64% |
| Dec 31, 2024 | -72.62% |
| Mar 31, 2023 | -3.79% |
| Dec 31, 2022 | -5.86% |
| Sep 30, 2022 | -15.60% |
| Jun 30, 2022 | -26.92% |
| Mar 31, 2022 | -6.73% |
| Dec 31, 2021 | -3.94% |
| Sep 30, 2021 | -11.08% |
| Jun 30, 2021 | -7.25% |
| Mar 31, 2021 | -10.00% |
| Dec 31, 2020 | 25.13% |
| Sep 30, 2020 | -16.01% |
| Jun 30, 2020 | 53.32% |
| Mar 31, 2020 | -72.77% |